The Lunar Meteoroid Impact Observer (LUMIO) is a CubeSat mission at the Earth-Moon Lagrangian point 2 (L 2 ) designed to observe, quantify, and characterize the meteoroid impacts by detecting their ...flashes on the Lunar farside. LUMIO can be deployed as one of the payloads in the NASA Commercial Lunar Payload System or from Artemis-2 mission to a low Lunar orbit and to demonstrate autonomous navigation capabilities to reach its operational orbit around the Earth-Moon L 2 . From there, its scientific mission to map and investigate the spatial and temporal characteristics of meteoroids impacting the Lunar surface will start and is expected to last for one year. LUMIO is a 12U CubeSat including a dedicated camera to monitor impact flashes in the visible and near-infrared spectrum, and also allows estimating the impact of temperature and energy. Optical navigation using the payload camera will also demonstrate increased on-board autonomy and drastically reduced mission costs. Navigation validation will be carried out using standard ground-based radiometric techniques enabled by a miniaturized X-band coherent transponder on-board. LUMIO can also use an inter-satellite link for telemetry and control via a commercial Lunar data relay system, providing a redundant communication system and lowering the need for high-gain ground stations for routine operations. The satellite bus derives from a commercial version designed for Low Earth Orbit and it will feature several improvements to operate in the Lunar environment, including a more advanced thermal control and radiation shielding. Commercial Off-The-Shelf systems will require a radiation screening and this will contribute to maintain the mission budget low and aim at a launch date in 2024.
Purpose
Acute appendicitis (AA) is among the most common causes of lower abdominal pain and admissions to the emergency department. Over the past 20 years, there has been a renewed interest in the ...conservative management of uncomplicated AA, and several studies demonstrated that an antibiotic-first strategy is a viable treatment option for uncomplicated AA. The aim of this prospective non-randomized controlled, multicenter trial is to compare antibiotic therapy and emergency appendectomy as treatment for patients with uncomplicated AA confirmed by US and/or CT or MRI scan.
Methods
All adult patients in the age range 18 to 65 years with suspected AA, consecutively admitted to the Surgical Department of the 13 participating Italian Hospitals, will be invited to take part in the study. A multicenter prospective collected registry developed by surgeons, radiologists, and pathologists with expertise in the diagnosis and treatment of uncomplicated acute appendicitis represents the best research method to assess the long-term role of antibiotics in the management of the disease. Comparison will be made between surgical and antibiotic-first approaches to uncomplicated AA through the analysis of the primary outcome measure of complication-free treatment success rate based on 1-year follow-up. Quality of life, length of hospital stay, pain evaluation, and time to return to normal activity will be evaluated as secondary outcome measures.
Trial registration
Clinicaltrials.gov
ID: NCT03080103
Diabetes and the Risk of Pancreatic Cancer Gullo, Lucio; Pezzilli, Raffaele; Morselli-Labate, Antonio Maria
The New England journal of medicine,
07/1994, Letnik:
331, Številka:
2
Journal Article
Recenzirano
Odprti dostop
Diabetes mellitus is known to occur more frequently in patients with pancreatic cancer than in the general population,
1
–
6
and it has repeatedly been claimed that diabetes is a risk factor for the ...tumor
6
–
18
. The increased frequency of diabetes in patients with pancreatic cancer is well established,
19
,
20
but the nature of this association is unknown
21
. A relevant question is whether diabetes in patients with pancreatic cancer represents a preexisting condition or whether it is secondary to the tumor. A corollary of this question is whether diabetes is a risk factor for pancreatic cancer. Several studies have . . .
Current data regarding an association between cholelithiasis, cholecystectomy, or gastrectomy and pancreatic cancer are conflicting. We evaluated the frequency with which these factors were present ...in 720 patients with newly diagnosed pancreatic cancer and in 720 matched controls. All subjects were interviewed personally and in detail about their clinical history. Cholelithiasis was present in 126 patients with pancreatic cancer (17.5%) and in 95 controls (13.2%), constituting a statistically significant association (odds ratio, 1.39; 95% confidence interval, 1.04-1.86); however, considering only the patients and controls in whom the diagnosis of cholelithiasis was made more than one year before cancer diagnosis or interview, the association was no longer significant (odds ratio, 1.04; 95% confidence interval, 0.75-1.44). Cholecystectomy had been performed in 93 patients with pancreatic cancer (12.9%) and in 71 controls (9.9%). When all subjects were considered, the odds ratio was mildly, although not significantly, increased (odds ratio, 1.35; 95% confidence interval, 0.97-1.87); when only subjects who underwent cholecystectomy one year or more before the cancer diagnosis or interview were considered, the odds ratio fell to unity. Gastrectomy had been performed in 28 patients with pancreatic cancer (3.9%) and in 25 controls (3.5%); analysis revealed no significant association between these two factors (odds ratio, 1.14; 95% confidence interval, 0.64-2.05). In conclusion, our study, one of the largest on this topic, has found no evidence for an association between cholelithiasis, cholecystectomy, or gastrectomy and pancreatic cancer.
PDF
